ROCKVILLE, Md., Sept. 10, 2004 (PRIMEZONE) -- Cytomedix, Inc. (OTCBB:CYME) today announced the opening of an office in Rockville, Maryland and the relocation of its office in Little Rock.
The Rockville office is located at 416 Hungerford Dr., Suite 330, Rockville, Maryland 20850. The new Little Rock office is located at 11809 Hinson Road, Suite 300, Little Rock, Arkansas 72212.
"Our new office in the greater Washington D.C. metropolitan area will enable Cytomedix to gain better access to regulatory agencies and take advantage of the numerous biotechnology resources in this geographic region. These factors are extremely important at this juncture in the company's evolution -- particularly given the current FDA-approved clinical trials for chronic wound treatment and other related applications for our technology moving forward," said Kshitij Mohan, Ph.D., president and chief executive officer of Cytomedix.
About Cytomedix
Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from autologous platelet releasates. The current product offering is the AutoloGel(tm) System, which produces an autologous platelet gel composed of multiple growth factors and fibrin matrix for treatment of chronic wounds. Cytomedix is working with healthcare providers to offer an advanced therapy at the point-of-care in multiple settings. Additional information is available at the company's website at www.cytomedix.com.
Forward Looking Statements
Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall with the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, governmental regulation, acceptance by the medical community and competition. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc.